; purpose (a) Findings Congress finds the following: (1) Cannabis was federally legal in the United States until 1937. (2) Cannabis was federally prohibited to codify discriminatory practices against minority communities. (3) Medical cannabis prohibition was established despite objection from the American Medical Association. (4) 37 States and the District of Columbia have legalized cannabis for medical purposes. (5) 18 States and the District of Columbia have legalized cannabis for adult use. (6) Despite the Federal Government collecting revenue from the sale of cannabis, individuals are still criminally persecuted for its use. (7) Cannabis research, including research on medical uses, product safety, and impairment standards, is severely hindered and made nearly impossible by its schedule 1 classification. (8) Cannabis should remain an adult product aside from the physician prescribed treatment of minors. (9) Cannabis has proven medically beneficial for patients suffering from pain, cancer, post-traumatic stress disorder, seizure disorders, and multiple sclerosis, among other diseases. (10) Since 2003, the United States Government by way of the Department of Health and Human Services has held a patent for medical cannabis as an antioxidant and neuroprotectant. (11) While the United States remains trapped in antiquated cannabis regulations, other nations and scientific competitors, including the United Kingdom, Canada, South Korea, Germany, and Israel have modified their laws to allow for varying degrees of cannabis legality and medical research. (b) Purpose The President and Congress shall prepare the Federal Government for an inevitable and prompt end to Federal marihuana prohibition by establishing a commission to advise on the development of a regulatory framework with respect to marihuana regulation, including accounting for the different characteristics of communities, agencies, and industries impacted by Federal marihuana prohibition. Such regulatory framework shall be modeled after Federal and State